Patents by Inventor Carl Pabo

Carl Pabo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7939327
    Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: May 10, 2011
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
  • Publication number: 20080233641
    Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.
    Type: Application
    Filed: February 28, 2008
    Publication date: September 25, 2008
    Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
  • Patent number: 7361635
    Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: April 22, 2008
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
  • Publication number: 20070178454
    Abstract: The present invention relates to methods of identifying multi-finger Zf polypeptides that bind to a sequence of interest. Zf polypeptides identified using the methods described herein can have affinity and specificity for their target sites that is superior to those produced by alternative methods.
    Type: Application
    Filed: October 23, 2003
    Publication date: August 2, 2007
    Inventors: J. Joung, Carl Pabo
  • Publication number: 20070150973
    Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.
    Type: Application
    Filed: March 7, 2006
    Publication date: June 28, 2007
    Inventors: Joel Pomerantz, Phillip Sharp, Carl Pabo
  • Publication number: 20070149770
    Abstract: Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain.
    Type: Application
    Filed: December 14, 2006
    Publication date: June 28, 2007
    Applicant: Massachusetts Institute of Technology
    Inventors: Jin-Soo Kim, Carl Pabo
  • Publication number: 20050202498
    Abstract: Polynucleotides encoding chimeric proteins, and methods for their production and use are disclosed. The chimeric proteins comprise a flexible linker between two zinc finger DNA-binding domains, wherein the linker contains eight or more amino acids between the second conserved histidine residue of the carboxy-terminal zinc finger of the first domain and the first conserved cysteine residue of the amino-terminal zinc finger of the second domain.
    Type: Application
    Filed: April 20, 2005
    Publication date: September 15, 2005
    Applicant: Massachusetts Institute of Technology
    Inventors: Jin-Soo Kim, Carl Pabo
  • Publication number: 20050064477
    Abstract: The present invention provides methods and compositions for interaction trap assays for detecting protein-protein, protein-DNA, or protein-RNA interactions. The methods and compositions of the invention may also be used to identify agents which may agonize or antagonize a protein-protein, protein-DNA, or protein-RNA interactions. In certain embodiments, the interaction trap system of the invention is useful for screening libraries with greater than 107 members. In other embodiments, the interaction trap system of the invention is used in conjunction with flow cytometry. The invention further provides a means for simultaneously screening a target protein or nucleic acid sequence for the ability to interact with two or more test proteins or nucleic acids.
    Type: Application
    Filed: August 10, 2004
    Publication date: March 24, 2005
    Inventors: J. Joung, Jeffrey Miller, Carl Pabo
  • Publication number: 20050064474
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Application
    Filed: August 6, 2004
    Publication date: March 24, 2005
    Inventors: Fyodor Urnov, Michael Holmes, Jeffrey Miller, Carl Pabo
  • Publication number: 20040091991
    Abstract: Disclosed herein are compositions and methods that regulate expression of two or more endogenous genes.
    Type: Application
    Filed: August 29, 2003
    Publication date: May 13, 2004
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Jeffrey Miller, Guofu Li, Carl Pabo, Trevor Collingwood
  • Patent number: 6316003
    Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which include HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
    Type: Grant
    Filed: April 28, 1994
    Date of Patent: November 13, 2001
    Assignees: Whitehead Institute for Biomedical Research, Johns Hopkins Univ. School of Medicine, Biogen, Inc.
    Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
  • Patent number: 5804604
    Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 8, 1998
    Assignee: Biogen, Inc.
    Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
  • Patent number: 5747641
    Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 5, 1998
    Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
  • Patent number: 5674980
    Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: October 7, 1997
    Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
  • Patent number: 5670617
    Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 23, 1997
    Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
  • Patent number: 5652122
    Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which comprise HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 29, 1997
    Inventors: Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky